Comparative Pharmacology
Head-to-head clinical analysis: TROVAN versus TROVAN PRESERVATIVE FREE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: TROVAN versus TROVAN PRESERVATIVE FREE.
TROVAN vs TROVAN PRESERVATIVE FREE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Trovan (trovafloxacin) is a fluoroquinolone antibiotic that inhibits bacterial DNA gyrase (topoisomerase II) and topoisomerase IV, thereby blocking DNA replication and transcription.
Inhibits DNA gyrase (topoisomerase II) and topoisomerase IV, thereby inhibiting bacterial DNA replication and transcription.
200 mg IV once daily for 7-14 days for community-acquired pneumonia; 200 mg orally once daily for 7-14 days for acute exacerbation of chronic bronchitis
200 mg intravenously once daily.
None Documented
None Documented
Terminal elimination half-life is approximately 10-12 hours in patients with normal renal function, supporting twice-daily dosing.
Terminal elimination half-life is approximately 10–13 hours in patients with normal renal function; prolonged in renal impairment.
Renal (approximately 60% unchanged) and fecal/biliary (approximately 35% as unchanged drug and metabolites).
Renal excretion accounts for approximately 90% of elimination, with ~50% as unchanged drug. Fecal/biliary excretion accounts for the remaining ~10%.
Category C
Category C
Antibiotic (Fluoroquinolone)
Antibiotic (Fluoroquinolone)